Search | Clinical Trials Finder

Conditions: HIV-1
Interventions: OZ1 transduced cells; Genetic
Lead sponsor: Janssen-Cilag Pty Ltd; Industry
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • New York, New York

Conditions: HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions: Bictegravir, emtricitabine, and tenofovir alafenamide; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more

Conditions: HiV1- Positive
Interventions: Abacavir/Lamivudine; Drug
Lead sponsor: Therapeutic Concepts; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Sargramostim; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 39
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 22 more

Conditions: HIV Infections, Pregnancy
Interventions: Indinavir sulfate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • The Bronx, New York

Conditions: HIV Infections
Interventions: Ritonavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 2 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 12
States / cities: Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more

Conditions: HIV Infections, Hemophilia A
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more

Conditions: HIV Infections
Interventions: EP HIV-1090; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island

Conditions: HIV-1 Infection
Interventions: Not listed
Lead sponsor: Prema Menezes, PhD, PA-C; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV-1 Infection
Interventions: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more

Conditions: HIV Infections
Interventions: HIV LFn-p24; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HIV Infections
Interventions: DTG + 3TC, TAF based regimen (TBR); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 54
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 44 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2005
U.S. locations: 13
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more

Conditions: HIV Infections
Interventions: Emtricitabine, Enfuvirtide, Ritonavir, Saquinavir, Tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 6
States / cities: Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, HIV-1 Immunogen, Nelfinavir mesylate; Drug · Biological
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections
Interventions: Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1999
U.S. locations: 11
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: HIV Infection
Interventions: Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: HTLV-I Infections, HTLV-II Infections, Human T-lymphotropic Virus 1, Human T-lymphotropic Virus 2, HTLV I Associated T Cell Leukemia Lymphoma, HTLV I Associated Myelopathies
Interventions: MP Diagnostics HTLV Blot 2.4; Diagnostic Test
Lead sponsor: MP Biomedicals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • San Antonio, Texas • Norfolk, Virginia

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Methemoglobinemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions: chemotherapy, dapsone, medical chart review, assessment of therapy complications; Drug · Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: Up to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: HIV-1 Infection
Interventions: FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Nelfinavir mesylate, Nevirapine, Azithromycin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult Non-Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Non-Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Non-Hodgkin Lymphoma
Interventions: C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs, Carmustine, Filgrastim, Laboratory Biomarker Analysis, O6-Benzylguanine, Plerixafor; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 66 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

The Effectiveness of GM-CSF in HIV-Positive Patients Who Are Also Receiving Anti-HIV Therapy

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection